Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03781700
Other study ID # FACE-01
Secondary ID 2017-004187-35
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 3, 2019
Est. completion date December 31, 2026

Study information

Verified date October 2023
Source Dalarna County Council, Sweden
Contact Barbro Hedin Skogman, MD, PhD
Phone +46 (0)23 49 20 00
Email barbro.hedinskogman@regiondalarna.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute facial nerve palsy occur in 10-20/100 000 children/year in Sweden. About 20 % of these children will have persistent symptoms with excessive tear secretion, drooling and social problems due to asymmetry in the face. Studies on cortisone treatment to adult patients with acute facial nerve palsy have shown beneficial effects, but no studies with strong quality have been performed in children. Investigators will perform a double-blind randomized placebo-controlled multicenter trial on children with acute facial nerve palsy. Participants will be recruited consecutively at 9-12 study centers in Sweden during 2019-2020. Oral cortisone (prednisolone) 1 mg/kg x 1 in 10 days (or placebo) will be started on admission. Clinical data, including recovery will be followed-up until 12 months. The primary outcome is defined as total recovery of the facial nerve palsy, measured with the House-Brackmann scale (grade 1) at 12-months follow-up. The overall purpose is to assess the utility of cortisone treatment given to children with acute facial nerve palsy in this study. If the total recovery rate is significantly improved in the prednisolone group as compared to the placebo group, prednisolone treatment will be introduced in clinical practice for children with acute facial nerve palsy in order to reduce the risk of persistent symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date December 31, 2026
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria: 1. 1-17 years of age 2. Acute peripheral unilateral facial nerve palsy 3. Less than 72 hours since debut of symptoms 4. Signed informed consent Exclusion Criteria: 1. Head trauma <1 month 2. Central or bilateral facial nerve palsy 3. Malformations in head and neck 4. Conditions not compatible with cortisone treatment (arterial hypertension, diabetes mellitus, psychiatric disorder, active or latent tuberculosis, intolerance of lactose) 5. Current or past oncological diagnosis 6. Other serious medical conditions (meningitis, encephalitis, stroke) 7. Acute otitis media 8. Signs of herpes simplex or varicella zoster infection (vesicles in the ear region) 9. Pregnancy or breastfeeding 10. Use of any systemic or inhaled steroids within 2 weeks prior onset of symptoms 11. Immunization with live vaccine 1 month prior onset of symptoms 12. Requirement of live vaccine within 2 months from start of experimental treatment (prednisolone or placebo) 13. Evaluation of primary endpoint at 12 months not feasible for any reason 14. Previously included into the FACE study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prednisolone
Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
Placebo Oral Tablet
Placebo tablets with identical appearance to the experimental drug

Locations

Country Name City State
Sweden Barn- och ungdomsmedicin Falun Dalarna
Sweden Barnmedicin Drottning Silvias Barn- och Ungdomssjukhus Östra Sjukhuset Göteborg
Sweden Barn- och ungdomsmedicinska kliniken Jönköping
Sweden Barn och ungdomskliniken, Länssjukhuset Kalmar Region Kalmar
Sweden Barn- och ungdomsmottagning Karlskrona
Sweden HKH Kronprinsessan Viktorias Barn- och ungdomssjukhus Linköping
Sweden Akutmottagning för barn, Skåne Universitets sjukhus Lund
Sweden Barnakuten i Malmö, Skåne Universitets sjukhus Malmö
Sweden Barn- och ungdomskliniken, Vrinnevi sjukhuset Norrköping
Sweden Barn- och ungdomskliniken, Universitets sjukhuset Örebro Örebro
Sweden Barnkliniken, Skaraborgs sjukhus Skövde Västra Götalands Region
Sweden Astrid Lindgrens barnsjukhus, Karolinska Solna Solna
Sweden Astrid Lindgrens barnsjukhus, Karolinska Huddinge Stockholm
Sweden Sachsska barnsjukhuset Stockholm
Sweden Akademisk Barnsjukhuset Uppsala

Sponsors (2)

Lead Sponsor Collaborator
Dalarna County Council, Sweden Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events Number of Adverse Events possibly or probably related to the study drug. Up to 12 month (+/- 2 weeks) after inclusion
Primary House-Brackmann scale Total recovery in the two treatment groups measured with the House-Brackmann scale.
The House-Brackmann scale (I is normal function and VI is total loss of function) is chosen as primary outcome measure since it is an objective instrument, easy to perform and the one most frequently used in previous studies. The time point 12 months for evaluation of total recovery is chosen as no further improvement of the facial nerve function is expected after 12 months.
At 12 months (+/- 2 weeks) after inclusion
Secondary Sunnybrook facial grading system Total recovery in the two treatment groups measured with the Sunnybrook scale.
The Sunnybrook scale (100 is normal function and 0 is total loss of function) is another objective scale for grading the facial nerve function. It will be used as secondary outcome measure. It is easy to perform and has been used in previous studies in children. It correlates well to the House-Brackmann scale.
At 12 months (+/- 2 weeks) after inclusion
Secondary Facial Disability Index (FDI) Disease-specific Quality-of-Life assessment scale, with 5 functional domains (5 means no probelms and 2 or 1 means problems all the time) and 5 social domains (6 means problems all the time and 1 means no problems at all) At 12 months (+/- 2 weeks) after inclusion
Secondary Facial Clinimetric Evaluation (FaCE) Scale Disease-specific Quality-of-Life assessment scale, with 15 functional and social domains (1 means problems all the time and 5 means no problems at all). At 12 months (+/- 2 weeks) after inclusion
Secondary Synkinesis Assessment Questionnaire (SAQ) Subjective grading of synkinesis symptoms with 9 functional domains (1 means no problems at all and 5 means problems all the time). At 12 month (+/- 2 weeks) after inclusion
See also
  Status Clinical Trial Phase
Completed NCT05679752 - Effects of Massage Therapy and Facial PNF in Early Bell's Palsy N/A
Terminated NCT03996525 - Electrical Stimulation to Improve Recovery After Peripheral Nerve Injury N/A
Enrolling by invitation NCT02179684 - Surgery or Clincial Follow up, in Patients With Bell' s Palsy N/A
Not yet recruiting NCT06063954 - Two Electroacupuncture Waveforms for Different Severity Groups of Bell Palsy N/A
Completed NCT04807491 - Kabat Technique and Neuromuscular Effect in Patients With Bell's Palsy N/A
Completed NCT03592797 - Effect of Laser Acupuncture Treatment on Chronic Facial Paralysis N/A
Recruiting NCT04406376 - Do We Need to Taper Down Steroid Therapy for Bell's Palsy Phase 4
Recruiting NCT06029855 - Kabat Rehabilitation Versus Mime Therapy on Facial Disability and Synkinesis in Patients of Bell's Palsy N/A
Recruiting NCT06459830 - Mime Therapy With and Without Neural Mobilization in Bell's Palsy. N/A
Recruiting NCT06340009 - MIME THERAPY vs MOTOR IMAGERY TECHNIQUE in Bell's Palsy N/A
Completed NCT04280120 - Effect of Neural Mobilization in Bells Palsy: A Randomized Controlled Trial N/A
Completed NCT05891106 - AONDA Therapeutic Indication Study I
Completed NCT03974763 - Function and Form Outcomes in Patients With Facial Paralysis
Active, not recruiting NCT05997199 - The Effect Vitamin D on the Recovery Rate of Bell Palsy
Completed NCT04412733 - EFFECTÄ°VENESS OF PULSED ULTRASOUND TREATMENT ON PATIENTS WITH BELL'S PALSY N/A
Recruiting NCT06028191 - Combined Effects of Low Level Laser Therapy and Kabat Technique in Patients With Bell's Palsy N/A
Recruiting NCT05582915 - Screening for Prognostic Biomarkers of Severe Bell's Palsy in Adults
Terminated NCT03836989 - Electrical Stimulation to Promote Recovery in Bells Palsy N/A
Recruiting NCT05270187 - Multiwave Locked System Laser for Patients With Bell's Palsy. N/A
Recruiting NCT06308250 - Comparative Effects of Mime Therapy and Action Observation Therapy in Bell's Palsy N/A